PA
MRNA icon

Pinnacle Associates’s Moderna MRNA Stock Holding History

Pinnacle Associates’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,880
Closed -$297K – 837
2023
Q3 		$297K Sell
2,880
-105
-4% -$11.7K 0.01% 677
2023
Q2 		$363K Buy
2,985
+346
+13% +$46.2K 0.01% 633
2023
Q1 		$405K Sell
2,639
-111
-4% -$18.3K 0.01% 562
2022
Q4 		$494K Sell
2,750
-307
-10% -$50.2K 0.01% 503
2022
Q3 		$361K Buy
3,057
+552
+22% +$83.8K 0.01% 561
2022
Q2 		$358K Sell
2,505
-258
-9% -$36.9K 0.01% 573
2022
Q1 		$476K Buy
2,763
+230
+9% +$38.7K 0.01% 574
2021
Q4 		$643K Buy
2,533
+682
+37% +$199K 0.01% 518
2021
Q3 		$712K Buy
1,851
+120
+7% +$44.3K 0.01% 501
2021
Q2 		$407K Buy
+1,731
New +$309K 0.01% 585

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Pinnacle Associates's MRNA Position: Q4 2023 in Review

Pinnacle Associates sold out of Moderna (MRNA) in Q4 2023, closing a stake of 2,880 shares — an estimated $297K sold.

Pinnacle Associates first reported a position in MRNA in Q2 2021 and held it in 10 quarters. The position peaked at $712K in Q3 2021. 884 funds tracked by Wall St. Rank hold MRNA as of Q4 2023.

  • Pinnacle Associates reported no remaining Moderna position as of Q4 2023 after selling out during the quarter.
  • Pinnacle Associates sold 2,880 Moderna shares in Q4 2023, an estimated $297K.
  • Pinnacle Associates first reported a position in Moderna in Q2 2021 and held it in 10 quarters.
  • Pinnacle Associates's Moderna position peaked at $712K in Q3 2021.
  • 884 funds tracked by Wall St. Rank held Moderna as of Q4 2023.

Based on Pinnacle Associates's 13F filing for Q4 2023, filed 19 Jan 2024.